Influenza B virus neuraminidase: a potential target for next-generation vaccines?
Expert Rev Vaccines
; 23(1): 39-48, 2024.
Article
in En
| MEDLINE
| ID: mdl-38037386
ABSTRACT
INTRODUCTION:
Influenza B viruses (IBV) cause a significant health and economic burden annually. Due to lower antigenic drift rate, less extensive antigenic diversity, and lack of animal reservoirs, the development of highly effective universal vaccines against IBV might be in reach. Current seasonal influenza vaccines are formulated to induce antibodies against the Hemagglutinin (HA) protein, but their effectiveness is reduced by mismatch between vaccine and circulating strains. AREAS COVERED Given antibodies against the Neuraminidase (NA) have been associated with protection during influenza infection, there is considerable interest in the development of NA-based influenza vaccines. This review summarizes insights into the role of NA-based immunity against IBV and highlights knowledge gaps that should be addressed to inform the design of next-generation influenza B vaccines. We discuss how antibodies recognize broadly cross-reactive epitopes on the NA and the lack of understanding of IBV NA antigenic evolution which would benefit vaccine development in the future. EXPERT OPINION Demonstrating NA antibodies as correlates of protection for IBV in humans would be paramount. Determining the extent of IBV NA antigenic evolution will be informative. Finally, it will be critical to determine optimal strategies for incorporating the appropriate NA antigens in existing clinically approved vaccine formulations.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Influenza Vaccines
/
Orthomyxoviridae Infections
/
Influenza, Human
Limits:
Animals
/
Humans
Language:
En
Journal:
Expert Rev Vaccines
Journal subject:
ALERGIA E IMUNOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Australia
Country of publication:
United kingdom